Compounded Semaglutide: Is It Safe? What to Know in 2026
A sourced guide to compounded semaglutide safety: FDA's stance, 503A vs 503B pharmacies, what to look for in a provider, and red flags to walk away from.
By Ruth Calder, Enforcement Editor
Our methodology sets out how these guides get researched and kept current.
Looking for a provider? Our 2026 comparison of the leading GLP-1 telehealth sellers is a click away.
Best (Verified) GLP-1 Providers →Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
If you've read anything about compounded GLP-1 medications, you've probably encountered scary headlines: FDA warnings, hospitalizations, lawsuits, conflicting court decisions. You've also probably encountered glowing testimonials from patients paying $149/month instead of $1,349/month for semaglutide that produced the same weight loss. So which is true?
Both are true, depending entirely on which compounding pharmacy is producing the medication and which telehealth provider is dispensing it. Compounded semaglutide can be safe and effective, or it can be dangerous and even fraudulent. The difference comes down to a handful of regulatory and operational details, set out below.
Every claim here is sourced. We're not affiliated with any compounding pharmacy. Our provider rankings score sellers on what they publish, including whether they name the pharmacy that fills their prescriptions.
Key Takeaways
- Compounded semaglutide is still legal in 2026 in narrow circumstances, mainly prescriptions compounded for individual patients, even though the parent drug is no longer on the FDA shortage list.
- 503B outsourcing facilities are FDA-registered and inspected, but they are not a lawful source of compounded semaglutide or tirzepatide in 2026. FDA says they may not compound either drug from bulk ingredients now that both shortages have ended.
- 503A pharmacies can compound for individual patients with documented medical need (e.g. allergies to inactive ingredients). This is the route left for compounded semaglutide.
- The biggest safety risks are not chemical. They are sourcing fraud, dosing errors from non-standard concentrations, and lack of medical oversight.
- Verify any provider via LegitScript and your state pharmacy board before paying.
- Avoid: "research peptides," Telegram/Reddit-only sellers, foreign pharmacies, providers with no licensed prescribers, and any source that ships without cold-chain packaging.
What "Compounded" Actually Means
To compound a drug is to combine or alter ingredients so the result fits one patient's particular needs. It is a centuries-old pharmacy practice and is fully legal in the United States under federal and state law.
There are two types of compounding facilities:
503A pharmacies
The name refers to a section of federal drug law: section 503A of the Food, Drug, and Cosmetic Act. A 503A pharmacy holds a state license and compounds for a named patient against a valid prescription. These pharmacies are regulated by state pharmacy boards (not the FDA directly) and cannot mass-produce medications: each compound must be tied to a specific patient prescription.
503B outsourcing facilities
These take their name from section 503B of the same Act. They register with the FDA and may compound in bulk without a prescription naming a patient. They are inspected by the FDA, must comply with current Good Manufacturing Practices (cGMP), and report adverse events to FAERS (the FDA's adverse event database).
That oversight does not make a 503B a source of compounded semaglutide today. An outsourcing facility may compound from bulk drug substance only for a substance that the 503B bulks list includes, or for a drug that FDA's shortage list includes, and FDA states that semaglutide and tirzepatide appear on neither. On April 30, 2026, FDA also proposed leaving semaglutide, tirzepatide and liraglutide off the 503B bulks list, saying outsourcing facilities have no clinical need to compound them from bulk.
While semaglutide was in shortage, many telehealth sellers filled orders through 503B facilities, and that was lawful at the time. It stopped being lawful when FDA's grace period for outsourcing facilities ended on May 22, 2025. A seller that still advertises "503B-made" semaglutide or tirzepatide owes you two answers: which facility makes it, and under what legal basis. If it can't give them, walk away.
The worst safety problems sit further down the chain, with unlicensed labs and with sellers who import API from gray-market suppliers.
The FDA's Position: Complicated
From 2022 until February 2025, semaglutide was on the FDA drug shortage list. Federal law (under section 503A and 503B) explicitly permits compounding of drugs on the shortage list, even if those drugs are FDA-approved and commercially available, because the rationale is patient access.
On February 21, 2025, the FDA declared the semaglutide shortage resolved. The Outsourcing Facilities Association challenged the decision in federal court, but in April 2025 the court denied its request for a preliminary injunction. The FDA's grace periods for compounders then ended: on April 22, 2025 for 503A pharmacies and on May 22, 2025 for 503B outsourcing facilities.
The legal and regulatory situation in 2026 is:
- 503B outsourcing facilities may not compound semaglutide or tirzepatide from bulk drug substance, because, the FDA says, neither drug appears on the 503B bulks list or its shortage list, and their products may not be essentially a copy of an FDA-approved drug. FDA proposed in April 2026 to exclude both from the bulks list.
- 503A pharmacies can compound semaglutide for an individual patient on a prescription. They may not regularly make copies of Wegovy or Ozempic unless the prescriber documents a significant difference for that patient (e.g. allergies to inactive ingredients in the brand product).
- The FDA has issued warnings about specific bad actors (mislabeled products, inappropriate dosing, fraudulent providers) but has not banned compounded semaglutide as a category.
This is a moving target, and the rules may change again in 2027. Check FDA's compounding policy page for GLP-1s for the current position.
What Could Actually Go Wrong
When compounded semaglutide hurts patients, the cause is almost never the molecule itself. Semaglutide is a well-characterized peptide, FDA-approved since 2017 and built on decades of GLP-1 research. The risks come from sourcing, manufacturing, and dispensing failures.
1. Mislabeled or contaminated API
The active pharmaceutical ingredient must be sourced from a licensed supplier with documented certificates of analysis. Gray-market API has been found to contain incorrect peptides, bacterial endotoxins, or wrong concentrations. A licensed pharmacy ought to be able to identify its API supplier and show the certificate of analysis; sketchy compounders skip this.
2. Wrong concentration → dosing errors
Brand Wegovy injections arrive as pre-filled pens, most holding one exact dose (0.25, 0.5, 1.0, 1.7, 2.4 or 7.2 mg). Compounded semaglutide is typically supplied as a multi-dose vial in mg/mL concentration. If the patient or telehealth provider miscalculates units, an overdose is possible. Several adverse events reported to the FDA were traced to this exact mistake.
3. Loss of cold chain
Semaglutide requires refrigeration (36–46°F) for stability. Shipping without cold-chain packaging can degrade the peptide and reduce efficacy. Reputable providers ship in insulated boxes with ice packs and require signature on delivery.
4. "Semaglutide" that isn't semaglutide
Some bad actors sell salt forms (semaglutide sodium, semaglutide acetate) that are not the same as the FDA-approved semaglutide base. These salt forms are not approved for human use. The FDA has issued specific warnings against compounded products containing semaglutide salts.
5. No real medical oversight
Legitimate telehealth providers have licensed prescribers (MD, NP, PA) review every patient intake. Some bad-actor websites use rubber-stamp "medical reviews" or skip the prescriber step entirely. Without a real prescriber, there's no one to catch contraindications, drug interactions, or dose-titration errors.
How to Verify a Provider Is Safe
Before signing up with any telehealth provider that offers compounded GLP-1, run through this checklist:
- LegitScript Healthcare Merchant Certification. LegitScript certifies telehealth providers and online pharmacies. Search the provider's domain on the LegitScript website. If they're not certified, walk away.
- Names a state-licensed 503A pharmacy you can check. The provider should tell you which pharmacy compounds your semaglutide. Look that pharmacy up in your state board of pharmacy's license database; FDA keeps links to every state's database. If the answer is a 503B outsourcing facility, ask how it is making semaglutide when FDA says it may not.
- Has licensed prescribers visible. Reputable providers list their medical leadership (medical director, prescriber team) by name and credential. Anonymous "care team" with no names is a red flag.
- Cold-chain shipping with signature. The provider should ship in insulated packaging with an ice pack and require a signature on delivery.
- Pre-filled syringes or clearly labeled vials. The provider should ship medication in a format that minimizes dosing errors. Look for pre-measured doses or clearly labeled multi-dose vials with patient-specific instructions.
- Real pricing transparency. Reputable providers list their pricing clearly. Sketchy ones bury the price behind a multi-step intake or quote different prices to different patients.
- Available in your state. If a provider claims to ship to all 50 states but their compounding pharmacy is only licensed in 20, they're cutting regulatory corners.
Our best GLP-1 providers ranking does not certify sellers against this list, so run the checks yourself before you pay.
These checks work the same on smaller sellers as on household names. You can run them on these compounded semaglutide sellers, each with a full review: Heros Health, which charges no separate membership fee, and Signos, which bundles the drug with a glucose monitor and app. Metaboost Rx, Superior Remedies and Pillar Health each charge one monthly price at every dose.
Bayan Health compounds its semaglutide with vitamin B6, so the vial label should say so. Loozy sells semaglutide as a 3-month starting plan, and Happy Care Meds sells a single 28-day supply with no subscription. SkyRx sells compounded semaglutide as an injection or oral drops, on a 12-month plan paid up front.
Red Flags That Should Make You Walk Away
- The website says "research peptide" or "not for human use"
- Sold via Telegram, Discord, or Reddit DMs
- Ships from outside the United States
- No medical intake or prescriber review
- Won't name the compounding pharmacy
- Says its semaglutide or tirzepatide is made by a 503B outsourcing facility and can't explain how that is allowed
- No cold-chain packaging
- Price is dramatically lower than the market norm (e.g. $39/month; there's no legitimate way to produce compounded semaglutide that cheaply)
- No company address, no licensed prescribers listed, no LegitScript certification
- Ships in glass vials with handwritten labels or no labels at all
Side Effects: Same as Brand-Name
When compounded semaglutide is produced correctly and sourced from a legitimate, licensed pharmacy, the side effect profile is identical to brand-name Ozempic and Wegovy: nausea, constipation, fatigue, occasional vomiting in the days after dose increases. Read our semaglutide side effects management guide for the full clinical picture.
If you have symptoms beyond the typical GI side effects, such as fever, severe abdominal pain, signs of infection at the injection site, sudden vision changes or a severe allergic reaction, stop the medication immediately and contact a doctor. These can indicate either a serious adverse drug reaction or a contamination event with the product itself.
Bottom Line
Compounded semaglutide can be safe when a state-licensed 503A pharmacy prepares it on your prescription and a licensed telehealth provider with real medical oversight dispenses it. It is dangerous when sourced from gray-market vendors, foreign pharmacies, or unlicensed labs. FDA says 503B outsourcing facilities may not compound semaglutide or tirzepatide from bulk in 2026, so a "503B" label on a compounded GLP-1 is a question to ask the seller.
For most patients in 2026, the safest path to affordable GLP-1 access is a telehealth provider that:
- Is LegitScript-certified
- Names the 503A pharmacy that compounds your medication, and that pharmacy is licensed in your state
- Employs licensed prescribers who review every intake
- Ships with cold-chain packaging and clear dosing instructions
Our best GLP-1 providers ranking scores sellers on what they publish, and our methodology page shows how each score is computed. And if you want to understand the broader cost landscape, see our guide on getting GLP-1 without insurance.
Sources & methodology — as of October 2026
- 1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Warning Letters Regarding Compounded GLP-1 Drug Products— U.S. Food & Drug Administration.
- 5.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
- 6.FDA Adverse Event Monitoring System (AEMS) Public Dashboard (formerly FAERS)— U.S. Food & Drug Administration.
- 7.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
Compare the sellers
Ready to compare GLP-1 providers?
Trust, support, availability, the medications carried and what they cost — we rank every major telehealth seller on all five, and refresh it each quarter. Nothing padded.
Best (Verified) GLP-1 Providers →Related guides
How to Pay for a GLP-1 Without Insurance: Savings Cards, Self-Pay and Compounded
Getting semaglutide, tirzepatide and other GLP-1s without insurance: compounded options, manufacturer coupons, and the cheapest legal paths.
How to Manage Semaglutide Side Effects, From Nausea to Constipation
A sourced guide to semaglutide side effects (nausea, constipation, fatigue, gallbladder, pancreatitis), with practical management steps and red flags.
Ozempic vs Wegovy Price: Why One Costs More
One molecule, semaglutide, sold under two names at different doses and approved by the FDA for different things. We explain the pricing arbitrage and which to choose.
Ozempic and Gallbladder Issues: What the Research Actually Shows
The elevated risk of gallbladder disease on GLP-1 drugs: what the JAMA meta-analysis found, why it happens, and who's at higher risk.
Read our methodology · affiliate disclosure · about us